A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
NCT ID: NCT06962280
Last Updated: 2025-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
465 participants
INTERVENTIONAL
2025-05-12
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tirzepatide
Participants will receive tirzepatide subcutaneously (SC)
Tirzepatide
Administered SC
Placebo
Participants will receive placebo SC
Placebo
Administered SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tirzepatide
Administered SC
Placebo
Administered SC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have an HbA1c value of 7.0% to 10.5% inclusive, at screening
* Have a body mass index (BMI) of ≥25 kilograms per square meter (kg/m2) at screening
* Are of stable weight for at least 90 days prior to screening and agree to not start an intensive diet or exercise program during the study
Exclusion Criteria
* Have experienced one or more events of severe hypoglycemia during the period of 90 days prior to screening and until randomization.
* Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
* Have had chronic or acute pancreatitis
* Have used any weight loss drugs or alternative remedies, including herbal or nutritional supplements, within 90 days prior to screening
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kaiser Permanente Bonita Medical Offices
Bonita, California, United States
AMCR Institute
Escondido, California, United States
Mary & Dick Allen Diabetes Center
Newport Beach, California, United States
University Clinical Investigators, Inc.
Tustin, California, United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Metabolic Research Institute, Inc.
West Palm Beach, Florida, United States
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, United States
HealthPartners Institute dba International Diabetes Center
Minneapolis, Minnesota, United States
Clinical Research Professionals
Chesterfield, Missouri, United States
Clinvest Headlands Llc
Springfield, Missouri, United States
Las Vegas Endocrinology
Henderson, Nevada, United States
University of North Carolina Medical Center
Chapel Hill, North Carolina, United States
Velocity Clinical Research, Dallas
Dallas, Texas, United States
Juno Research
Houston, Texas, United States
Southern Endocrinology Associates
Mesquite, Texas, United States
Texas Diabetes & Endocrinology, P.A.
Round Rock, Texas, United States
San Antonio Clinical Trials
San Antonio, Texas, United States
Texas Valley Clinical Research
Weslaco, Texas, United States
Buenos Aires Macula S.A
Buenos Aires, , Argentina
Stat Research S.A.
Buenos Aires, , Argentina
Mautalen Salud e Investigación
Buenos Aires, , Argentina
Centro Diabetológico Dr. Waitman
Córdoba, , Argentina
CIPADI - Centro Integral de Prevencion y Atencion en Diabetes
Godoy Cruz, , Argentina
Centro de Investigaciones Clínicas Baigorria
Granadero Baigorria, , Argentina
Instituto Médico Catamarca IMEC
Rosario, , Argentina
Investigaciones Clínicas Tucumán
San Miguel de Tucumán, , Argentina
Centro de Pesquisa Clinica do Brasil
Brasília, , Brazil
Centro de Pesquisa Sao Lucas
Campinas, , Brazil
Quanta Diagnóstico e Terapia
Curitiba, , Brazil
Cendi - Endocrinologia e Diabetes
Goiânia, , Brazil
Instituto da Crianca com Diabetes
Porto Alegre, , Brazil
IBPClin - Instituto Brasil de Pesquisa Clínica
Rio de Janeiro, , Brazil
CPCLIN
São Paulo, , Brazil
CEPIC - Centro Paulista de Investigação Clínica
São Paulo, , Brazil
Endocrinologie Oasis
Montreal, , Canada
Centricity Research Ottawa LMC Endocrinology
Ottawa, , Canada
Centre de Recherche Saint-Louis
Sherbrooke, , Canada
TLC Diabetes and Endocrinology
Surrey, , Canada
Care Access - Cape Breton
Sydney, , Canada
INTENDIA klinika s.r.o.
Chrudim III, , Czechia
AIDIN VK s.r.o.
Hranice, , Czechia
MUDr. Tomas Edelsberger
Krnov, , Czechia
Diabetologicke centrum s.r.o.
Olomouc, , Czechia
Milan Kvapil s.r.o., Diabetologicka ambulance
Prague, , Czechia
ResTrial s.r.o.
Prague, , Czechia
Centre Hospitalier Universitaire - Hôpitaux de Rouen - Hôpital de Bois-Guillaume
Bois-Guillaume, , France
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, , France
Centre Hospitalier Universitaire de Grenoble
Grenoble, , France
Hôtel-Dieu du Creusot - site Harfleur
Le Creusot, , France
Hôpital de la Conception
Marseille, , France
Assistance Publique Hôpitaux de Paris - Groupe Hospitalier 10e - Hôpital Lariboisière
Paris, , France
CHU Rangueil
Toulouse, , France
Groupe Hospitalier Mutualiste Les Portes du Sud
Vénissieux, , France
Athens Medical Center
Athens, , Greece
Iatriko Paleou Falirou Medical Center
Palaió Fáliro, , Greece
Euromedica General Clinic of Thessaloniki
Thessaloniki, , Greece
Ippokrateio General Hospital of Thessaloniki
Thessaloniki, , Greece
Enclifar Ensayos Clínicos Farmacológicos Sc
Chihuahua City, , Mexico
Unidad de Investigaci�n Cl�nica Cardiometabolica de Occidente
Guadalajara, , Mexico
Private Practice - Dr. Arechavaleta Granell Maria del Rosario
Guadalajara, , Mexico
Unidad de Investigación Clínica y Atención Médica HEPA S.C.
Guadalajara, , Mexico
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Mexico City, , Mexico
CEINV Salud
Monterrey, , Mexico
Clínica García Flores SC
Monterrey, , Mexico
Consultorio Médico de Endocrinología y Pediatría
Puebla City, , Mexico
Medsal Centro Médico
Tampico, , Mexico
CMI DNBM Dr. Pop Lavinia
Baia Mare, , Romania
Mariodiab Clinic
Brasov, , Romania
Centrul medical DiabNutriMed
Bucharest, , Romania
Diabet Med
Bucharest, , Romania
Sanamed Hospital
Bucharest, , Romania
Diamed Obesity
Galați, , Romania
Centrul Medical Consultmed
Iași, , Romania
Rinart Diab SRL
Târgovişte, , Romania
Hospital Infanta Cristina
Badajoz, , Spain
Hospital Germans Trias i Pujol
Badalona, , Spain
Hospital Clínic de Barcelona
Barcelona, , Spain
Hospital Universitario Ramón y Cajal
Madrid, , Spain
Hospital Universitario Virgen Del Rocio
Seville, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role: CONTACT
Phone: 1-317-615-4559
Email: [email protected]
Physicians interested in becoming principal investigators please contact
Role: CONTACT
Email: [email protected]
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-2)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-519685-51-00
Identifier Type: CTIS
Identifier Source: secondary_id
I8F-MC-GPJD
Identifier Type: OTHER
Identifier Source: secondary_id
27340
Identifier Type: -
Identifier Source: org_study_id